



HAL
open science

Preclinical pharmacology of a lipophenol in a mouse model of light-induced retinopathy

Nicolas Taveau, Aurélie Cubizolle, Laurent Guillou, Nicolas Pinquier, Espérance Moine, David Cia, Vasiliki Kalatzis, Joseph Vercauteren, Thierry Durand, Céline Crauste, et al.

► **To cite this version:**

Nicolas Taveau, Aurélie Cubizolle, Laurent Guillou, Nicolas Pinquier, Espérance Moine, et al.. Pre-clinical pharmacology of a lipophenol in a mouse model of light-induced retinopathy. *Experimental & Molecular Medicine*, 2020, 52, pp.1090 - 1101. 10.1038/s12276-020-0460-7. hal-03071488

HAL Id: hal-03071488

<https://hal.science/hal-03071488v1>

Submitted on 16 Dec 2020


HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

ARTICLE

Open Access

Preclinical pharmacology of a lipophenol in a mouse model of light-induced retinopathy

Nicolas Taveau^{1,2}, Aurélie Cubizolle^{1,2}, Laurent Guillou^{1,2}, Nicolas Pinquier¹, Espérance Moine³, David Cia⁴, Vasiliki Kalatzis^{1,2}, Joseph Vercauteren³, Thierry Durand³, Céline Crauste³ and Philippe Brabet^{1,2} 

Abstract

Environmental light has deleterious effects on the outer retina in human retinopathies, such as *ABCA4*-related Stargardt's disease and dry age-related macular degeneration. These effects involve carbonyl and oxidative stress, which contribute to retinal cell death and vision loss. Here, we used an albino *Abca4*^{-/-} mouse model, the outer retina of which shows susceptibility to acute photodamage, to test the protective efficacy of a new polyunsaturated fatty acid lipophenol derivative. Anatomical and functional analyses demonstrated that a single intravenous injection of isopropyl-phloroglucinol-DHA, termed IP-DHA, dose-dependently decreased light-induced photoreceptor degeneration and preserved visual sensitivity. This protective effect persisted for 3 months. IP-DHA did not affect the kinetics of the visual cycle *in vivo* or the activity of the RPE65 isomerase *in vitro*. Moreover, IP-DHA administered by oral gavage showed significant protection of photoreceptors against acute light damage. In conclusion, short-term tests in *Abca4*-deficient mice, following single-dose administration and light exposure, identify IP-DHA as a therapeutic agent for the prevention of retinal degeneration.

Introduction

Light-induced retinal degeneration is a pathophysiological condition that affects both young and elderly people¹. The same molecular and cellular mechanisms are often involved. In all cases, toxic photoproducts arise from vitamin A metabolites (carbonyl stressors) and oxidative stress, both of which lead to the death of outer retina cells, i.e., the retinal pigment epithelium (RPE) and photoreceptors. In young patients with autosomal recessive Stargardt's disease (STGD1), the most common juvenile macular dystrophy, and in elderly patients with advanced aged-related macular degeneration (AMD), high levels of photoreactive metabolites in the retina enhance light-induced susceptibility².

Photochemical mechanisms in the retina depend on oxygen concentration and photopigments. The high oxygen tension supplied from the dense vascular bed of the choroid exposes the outer retina to oxidation. Retinal photodamage is accompanied by lipid peroxidation³, suggesting that this photodamage is mediated by reactive oxygen species (ROS). Oxidative stress appears to be an early event in the retinal light damage process. There are several chromophores that absorb visible light in the outer retina, and their potential involvement in retinal photodamage was previously discussed⁴. Studies report that rhodopsin (the visual pigment) plays a critical role in photodamage^{5,6}. However, the photochemical properties of rhodopsin exclude it as the photosensitizer responsible for retinal photodamage⁷. Rather, the bleaching products of rhodopsin have been suggested to be photodamage mediators^{4,8}.

All-*trans*-retinal (*atRAL*) is one of the products of rhodopsin photobleaching, a toxic aldehyde and a potent photosensitizer⁹. *atRAL* forms in the photoreceptor outer segments (POS) by rhodopsin bleaching as the result of

Correspondence: Philippe Brabet (philippe.brabet@inserm.fr)

¹Institut des Neurosciences de Montpellier, INSERM U1051, F-34091 Montpellier, France

²Université de Montpellier, F-34091 Montpellier, France


Full list of author information is available at the end of the article

These authors contributed equally: Nicolas Taveau, Aurélie Cubizolle, Céline Crauste, Philippe Brabet

© The Author(s) 2020



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.



the photoisomerization of 11-*cis*-retinal (11cRAL), the visual pigment chromophore linked to opsin by Schiff base reaction¹⁰ (Scheme 1). Hydrolysis then releases *atRAL* from the opsin protein, *atRAL* which then transiently accumulates in the inner leaflet of the POS disc membranes¹¹. The accumulation of free *atRAL* can impose a risk of photooxidative damage to the retina induced by visible light⁹. The photodegradation of *atRAL* can generate singlet oxygen and superoxide, which cause oxidative damage to cellular components.

Alternatively, the free *atRAL* in the outer segments of the photoreceptors may react by condensation with phosphatidylethanolamine (PE) to form N-Retinylidene PE (NRetPE) (Scheme 1). The latter is the substrate for ABCR, the product of the ATP-binding cassette transporter A4 gene, *ABCA4*. ABCR is a flippase that facilitates NRetPE hydrolysis and *atRAL* release¹², which is then reduced to all-trans-retinol (*atROL*) by NADPH-dependent retinol dehydrogenases¹³. This reduction is the first limiting step of the visual (retinoid) cycle, a metabolic process that provides 11cRAL to regenerate visual pigments¹⁴. However, deficiency of *ABCA4*, as in the case of STGD1, strongly slows the clearance of *atRAL* in POS and increases susceptibility of the retina to photodamage¹⁵. Another effect induced by the accumulation of *atRAL* in POS is an increase in lipofuscin bis-retinoid pigments in the RPE¹⁶. The bis-retinoid A2PE, which

arises from the condensation of two *atRAL*s with PE, following phagocytosis by RPE, generates A2E, a blue light-sensitive chromophore (430–470 nm), found in lipofuscin and toxic to the RPE¹⁷.

Recent reports have shown that the sequestration of *atRAL* with primary amines or the inhibition of the visual cycle isomerase RPE65, the second limiting step of the 11cRAL regenerative process, can lower the *atRAL* concentration to safe levels and prevent retinal degeneration in mutant mice^{18,19}. Drugs that sequester *atRAL* contribute to the prevention of light-induced damage²⁰. The identification of new classes of sequestering compounds would be relevant to future therapies for macular dystrophies²¹. Previously, we described the protective effect of a docosahexaenoic acid (DHA) lipophenol conjugate, IP-DHA, on ARPE-19 cells challenged with a toxic concentration of *atRAL*²². More recently, we reported that IP-DHA can reduce the toxicity of *atRAL* by acting either as an *atRAL* or ROS scavenger or as an Nrf2-mediated enzyme defense inducer²³, which mediates the transcription of antioxidant/cytoprotective genes²⁴.

Here, we studied the therapeutic effects of IP-DHA on acute retinopathy using the *Abca4* knockout (*Abca4*^{-/-}) mouse model. We demonstrate that a single intravenous injection of IP-DHA reduced the photoreceptor loss induced by light exposure and preserved visual function over time. Furthermore, IP-DHA did not affect the

retinoid visual cycle. Moreover, IP-DHA administered by oral gavage using a nonoptimized formulation showed significant protection of photoreceptors.

Materials and methods

Chemicals

IP-DHA was synthesized and purified as previously described²². IP-DHA-*at*RAL adducts were synthesized from isopropyl-phloroglucinol, as described in the supplemental material. DHA ethyl ester, generously gifted by Vincent Rioux (Agrocampus Ouest, Rennes, France), was purified using an n-3 polyunsaturated fatty acid (PUFA) marine oil (Omegavie 4020EE Qualitysilver, Polaris) process, as described²⁵. Emixustat hydrochloride was purchased from Ambinter (Amb24183355, GreenPharma Orleans). Fatty acid-free bovine serum albumin (BSA) was purchased from Sigma-Aldrich (# A8806). *At*RAL and all-*trans*-retinyl palmitate (*at*RPalm) standards were purchased from Sigma-Aldrich (# R2500 and R3375, respectively), whereas 11*c*RAL was generously gifted by Rosalie Crouch (University of South Carolina, SC, USA). DPBS (1 X from Gibco, ref 14190-094) was the dilution buffer. Tropicamide (Mydriaticum 0.5% eye drops, Thea) was used to dilate the pupils, and ketamine (Imalgene 1000, Merial), xylazine (Rompun 2%, Bayer Healthcare), and cebesine (0.4% eye drops, Bausch and Lomb) were used to anesthetize the mice.

Abca4 knockout mice

Albino *Abca4*^{+/-} mice, bred from a mixed 129/S5 × C57BL/6J-*Tyr*^{c-Brd} background, were purchased from Taconic Biosciences Inc. Mice were reared and genotyped for the *Abca4* null mutation and were homozygous for Rpe65-Leu450. The lack of expression of the ABCR protein in the retina of *Abca4*^{-/-} mice was confirmed by western blot analysis (Anti-ABCA4 antibody [3F4], Novus Biologicals NBP1-30032, 1/1000; K. Damodar, personal communication). The rd8 mutant was absent in this *Abca4*^{-/-} line. Mice were subjected to standard 12-h light (90 lux) and 12-h dark cycles at a room temperature of ~22 °C and fed a standard rodent diet (SAFE 04) without DHA ad libitum. The mice were housed in facilities accredited by the French Ministry of Agriculture and Forestry (no C34-17236 – 19 December 2014). The care and use of animals was performed according to the European Directive 2010/63/EU, and the experimental procedures were approved by the French Ministry of National Education and Research (APAFIS #15117-2018051712092842v3).

IP-DHA administration

Mice between 9 and 12 weeks of age, of both sexes, were weighed to adjust the quantity of administered compound.

For intravenous injection, the mice were divided into untreated, BSA-treated, and treated groups with IP-DHA

at doses ranging from 5 to 30 mg/kg. IP-DHA was dissolved in absolute ethanol (0.1 mg/μl); the volume required for one dose of IP-DHA was mixed in sterile PBS with 0.175 g/ml lipid-free BSA in a molar ratio of 1/1–5/1 (IP-DHA/BSA). This mixture was vortexed for 2 min and incubated at 37 °C for 2 h. We assumed that IP-DHA behaves like DHA by forming complexes with BSA at the appropriate concentrations, as previously described²⁶, and 100 μl was injected into the tail vein 5–10 min before exposure to light.

For oral administration, the mice were orally gavaged with a 22-gauge needle containing 100 μL of soybean oil as a control vehicle (SIO, 62053 St-Laurent-Blangy, France); emixustat (40 mg/kg) suspended in DMSO, replenished in soybean oil and containing less than 10% (v/v) DMSO; IP-DHA or DHA-ethyl ester (between 40 and 150 mg/kg) directly suspended in soybean oil.

Light-induced retinal degeneration

After the mice were dark adapted (DA) for 24–48 h, their pupils were dilated with 0.5% tropicamide. The mice were injected with the IP-DHA/BSA complex in the dark, and then exposed to constant light (2 cool white fluorescent lamps, OSRAM of 26 watts, 1800 lm, maximum photopic efficiency of ~470 nm, light intensity averaged 24 mW/cm² corresponding to ~20,000 lux) for 2 h in a white plastic bucket with a fan. Mice were kept in the dark for 5 days before we performed final retinal evaluations. Throughout the experiment, the ambient temperature was 22 °C, identical to that of the breeding box, to avoid an increase in body temperature, which could further damage the retina⁵.

Histological analysis

All animals were killed by cervical dislocation. The eyes were rapidly enucleated and fixed in 4% paraformaldehyde for 24 h at 4 °C. Eye cups were embedded in paraffin and cut into 5 μm sagittal sections. For hematoxylin/eosin/saffron (HES) staining, the sections were deparaffined, labeled with HES using standard protocols, rinsed and mounted in Moeviol.

Spectral-domain optical coherence tomography (SD-OCT)

Spectral-domain optical coherence tomography (SD-OCT) was performed separately on each eye using an Envisu R2000 SD-OCT device (Bioptigen, Durham, NC). The pupils were dilated by applying 0.5% tropicamide to the cornea. The mice were anesthetized by an intraperitoneal injection of a mixture of ketamine (70 mg/kg) and xylazine (14 mg/kg), and local anesthesia was performed with a drop of oxybuprocaine (0.4% cebesine) on the cornea. Corneal hydration was maintained with Systane Ultra (Alcon, Fort Worth, TX) lubricant eye drops. Animal preparation and image acquisition were performed as

previously described²⁷. Analyses were performed using a rectangular scanning protocol (1.4 mm × 1.4 mm with 1000 A-scans per B-scan × 100 B-scans) while centered on the optic nerve. The thickness of the inner nuclear layer (INL), outer nuclear layer (ONL), and photoreceptor segments (PS = IS + OS) was measured and expressed in arbitrary units using ImageJ software. Twenty measurements were performed per analysis and averaged for both eyes.

Electroretinography

All electrophysiological examinations were conducted using the Visiosystem (SIEM, France). Animals were prepared and anesthetized, and electroretinogram recording (binocular full-field ERG) was performed with cotton electrodes, as previously described²⁸.

Retinoid analysis

The mice were killed by cervical dislocation before the eyes were rapidly enucleated, frozen in liquid nitrogen, and stored at -80°C until use. Retinoids were extracted from eyes as described²⁹ and quantified from the peak areas using calibration curves determined with established standards. An A2E assay was performed on six eyes per genotype (wild type or *Abca4*^{-/-}). Eyes were homogenized in 500 μl of absolute ethanol and centrifuged, and ethanol extracts were concentrated using a SpeedVac AES1000 (Savant Instruments, Saroo Nagar). The residual volume ($\sim 20\ \mu\text{l}$) was analyzed by reverse-phase HPLC. The absorbance of A2E and iso-A2E was measured at 430 nm, and A2E was quantified from the peak area using a calibration curve determined with synthetic A2E.

Statistics

Statistical analyses were performed using Graph Pad Prism 5.0 software. The data of two samples were first analyzed with the Shapiro–Wilk normality test, and then two-tailed *p*-values were determined using either an unpaired Student's *t* test or a nonparametric Mann–Whitney test. One-way ANOVA was used to compare more than two samples. Bonferroni's or Dunn's multicomparison adjustment was used as the post hoc test to calculate the significance levels. A *p*-value of < 0.05 was considered significant. The linear correlation was measured by Pearson's *r* correlation coefficient.

Results

The light-induced retinal damage paradigm

The albino *Abca4*^{-/-} mice, an animal model of Star-gardt's disease, used herein had a *atRAL* level similar to that of wild-type mice in adulthood (6–7 months) but had significantly lower 11cRAL levels and accumulated A2E faster, according to a recent report (Supplementary Fig. S1a, S1b)^{30–32}. However, there was no photoreceptor

degeneration in the mice before 10 months of age (Supplementary Fig. S1c)³³, suggesting that the level of A2E accumulation was too low to induce toxicity or that it was well tolerated in the outer retina. Therefore, to test the protective effect of IP-DHA on photoreceptor cells, we used a paradigm of acute retinal damage induced by light in mice aged 9–12 weeks (see Material and methods section). These mice were reared in darkness for 24–48 h, an appropriate amount of time for regenerating the visual pigment (opsin + 11cRAL), and then exposed to bright light. The overproduction and photooxidation of *atRAL* caused by intense light illumination and the genetic defect in the *Abca4* gene can induce delayed photoreceptor degeneration, which was quantified after 5 days in the dark by retinal histological analysis (Fig. 1). Light exposure for 2 h produced a reduction in the thickness of the photoreceptor ONL, which was $58.0 \pm 0.2\%$ of that of mice not exposed to light. Exposure for 1 h caused only a $10.0 \pm 0.4\%$ reduction. The ONL/INL ratio represents the OCT results with the thickness of the INL used as an internal standard as it does not significantly change after light exposure. All protective assessments were therefore conducted after a 2-h light exposure.

IP-DHA treatment prevents light-induced acute retinal degeneration

IP-DHA is an oily compound that is poorly soluble in water because of its long PUFA chain (DHA). To test its effect on acute light-induced damage, IP-DHA was complexed to defatted BSA and administered in the dark by intravenous injection in the tail vein as a single dose (5–30 mg/kg) prior to light exposure. Five days post-light exposure, the mice were evaluated by in vivo retinal imaging by histological analysis (Fig. 2), spectral-domain optical coherence tomography (SD-OCT, Fig. 3), and full-field electroretinography (ERG, Fig. 4). Whereas BSA injection did not prevent retinal degeneration and induced an average loss of photoreceptors comparable to no injection ($57.9 \pm 6.8\%$ and $56.4 \pm 2.5\%$, respectively, BSA vs NI, Fig. 2b), IP-DHA prevented light-induced acute degeneration and enabled the recovery of 80–85% of intact photoreceptors in a dose-dependent manner (Figs. 2b and 3b). IP-DHA injection markedly rescued the b-wave and a-wave amplitudes (Fig. 4a, b). A strong correlation between anatomical (ONL/INL) and functional (ERG) measurements suggested that the conservation of light-detecting photoreceptor cells was the cause of visual sensitivity rescue (Fig. S2). The level of 11cRAL was also well correlated with the a-wave amplitude, making 11cRAL a biomarker of photoreceptor status. The rescue of photoreceptor function (a-wave amplitude) lasted for at least 3 months postinjection (Fig. 5). By contrast, the visual function of untreated and BSA-treated mice was unchanged, indicating a permanent deficit that




Fig. 1 Susceptibility of retinæ from *Abca4*^{-/-} mice to acute light-induced degeneration. **a** Representative hematoxylin/eosin/saffron (HES)-stained retinal sections from *Abca4*^{-/-} mice after dark adaptation (DA) or bright light exposure (LE) for 1 or 2 h followed by darkness for 5 days. ONL outer nuclear layer, INL inner nuclear layer, GCL ganglion cell layer. **b** Quantification of photoreceptor loss measured as a ratio of outer and inner nuclear layer thickness (ONL/INL) under the conditions stated in **a**. The INL thickness did not change significantly with light exposure and was used as the internal reference. Light exposure for 2 h significantly decreased ONL thickness compared to the DA control condition and 1-h light exposure. The data are presented as a scatterplot, and red bars indicate the mean \pm SEM from $n \geq 30$ ratios, *** $p < 0.001$ one-way ANOVA with Bonferroni's posttest.





Fig. 2 Histological analysis of retinæ after light-induced acute retinal degeneration. **a** HES staining of retinal sections from *Abca4*^{-/-} mice that were dark-adapted (DA) or injected with BSA (BSA) or 25 mg/kg IP-DHA (IP-DHA 25) before light exposure. **b** IP-DHA treatment prevented the thinning of the outer nuclear layer (ONL), which contains photoreceptors, in untreated or BSA-treated mice. The data are presented as scatterplots, and horizontal bars indicate the mean \pm SEM from $n \geq 6$ mice. One-way ANOVA with Bonferroni's test: ### $p < 0.001$ vs. DA; *** $p < 0.001$ vs IP-DHA.

lasted more than 3 months after light exposure. During these 3 months, the mice showed normal weight gains and were generally indistinguishable from each other. Overall,

this posttreatment follow-up does not suggest any adverse dose-related effects. Collectively, these results emphasize the efficacy of IP-DHA in preventing acute retinal damage



and support the protective effect of therapy with this compound.

Protection in mice does not affect the retinoid cycle

We asked whether IP-DHA might react in vivo with *atRAL* and impair chromophore regeneration. By exposing the mice to bright light for 2 min, *atRAL* reached maximum levels prior to its reduction (Supplementary Fig. S3a). We then returned the mice to the dark for several hours before HPLC analysis of retinoid levels (Figs. S3b and 6). Chromophore 11cRAL levels decreased by $\sim 90\%$ after bleaching and then regenerated within the first hour of dark adaptation, whereas *atRPalm* accumulated postbleaching and did not return to baseline levels until 24 h postadaptation (Fig. 6a, b). By contrast, *atRAL* increased after bleaching and declined rapidly to basal levels after 1 h of dark adaptation (Fig. 6c). IP-DHA tended to reduce *atRAL* in the dark before and after bleaching, but this effect was not significant. We conclude that IP-DHA might partially reduce *atRAL* without affecting the retinoid cycle.

Comparative effects of IP-DHA and emixustat by oral pretreatment

A comparison of IP-DHA with emixustat (EMX), well known to have protective effects against acute light-induced retinal degeneration¹⁹, showed that these treatments had similar effects (Fig. 7). Both compounds generated higher a-wave amplitudes in the rod and cone ERG responses than did the oil vehicle ($p < 0.001$). EMX

treatment (40 mg/kg) by oral gavage 24 h before light exposure protected more than 90% of the photoreceptor response, which was not significantly different from the photoreceptor response of unexposed mice (DA). IP-DHA showed a dose-dependent effect after 6 h of pretreatment, protecting up to 70% of the photoreceptor ERG response at the highest dose (150 mg/kg). Thus, even in the absence of an optimized oral formulation, IP-DHA had a protective effect against light-induced retinal degeneration, which was promising. Remarkably, DHA ethyl ester (Et-ODHA, 150 mg/kg) had no protective effect, suggesting that simple DHA supplementation is not sufficient to provide photoreceptor protection and thus that the isopropyl-phloroglucinol moiety is a necessary part of the lipophenol structure to observe IP-DHA activity.

Effect of emixustat and IP-DHA on RPE65 isomerase

EMX is a visual cycle modulator that inhibits the RPE65 isomerase of the visual cycle, slows the regeneration of 11cRAL and thus limits the rate of *atRAL* produced by light³⁴. A first explanation for the difference in the protective efficacies of EMX and IP-DHA may be the inhibition of RPE65. We thus tested whether we could reproduce the inhibitory effect of EMX in HEK cells expressing LRAT and RPE65 (HEK-LR) and compared the inhibitory effect of EMX to that of IP-DHA in this model. HEK-LR cells were incubated initially with 40 μ M EMX or with 40–80 μ M IP-DHA for 24 h and then with 10 μ M vitamin A for an additional 24 h. Retinoids were





Fig. 4 Full-field ERG recordings after light-induced acute retinal degeneration. **a** Full-field ERG responses of IP-DHA (25 mg/kg)-treated or BSA-treated *Abca4*^{-/-} mice following light exposure were recorded under scotopic conditions and compared to nonexposed (DA) and noninjected (NI) light-exposed littermates. Data are representative ERG responses from left eyes (OS) to a light intensity of 0 to 2-log cd.s.m^{-2} . Amplitude scale, 1 div = 156 μV . **b** ERG b-wave amplitudes plotted as a function of light intensity were fully preserved in IP-DHA 25-treated *Abca4*^{-/-} mice compared to BSA-treated animals. Error bars indicate the SEM of the means ($n \geq 5$). **c** The dose-dependent protection of ERG a-wave amplitudes by IP-DHA at 2-log cd.s.m^{-2} . Error bars indicate the SEM ($n \geq 5$). One-way ANOVA with Bonferroni's multiple comparison posttest: ### $p < 0.001$ BSA vs. DA mice; * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$ IP-DHA versus BSA-treated mice; BSA vs. IP-DHA 5 nonsignificant, ns.

extracted from cell lysates and analyzed by normal-phase HPLC. As shown in Fig. 8, neither IP-DHA nor EMX affected the production of *atRPalm* catalyzed by LRAT, and only EMX significantly inhibited the formation of 11cROL catalyzed by RPE65. Therefore, our data show that IP-DHA does not affect RPE65 isomerase in vitro, unlike EMX.

Discussion

In the present study, we evaluated the therapeutic efficacy of a new small molecule, a phloroglucinol derivative, referred to as lipophenol (or phenolipid). The isopropyl function of this molecule reinforces the nucleophilic nature of its

aromatic ring, and DHA should improve its bioavailability and its capacity to reach the outer retina. Our previous in vitro evaluation of cultured retinal cells has shown that this lipophenol reduces the toxicity of *atRAL* (anti-carbonyl stress activity) and activates redox enzymes to promote antioxidant defenses²³. We continued this preclinical evaluation with an in vivo study in mice using a light-induced photoreceptor degeneration model in the context of an *Abca4* gene deletion that mimics human STGD1. Here, we will discuss the relevance of the mouse model as well as the structure-function relationship of lipophenol, its mode of action, and its comparison with small molecules already used in the treatment of macular degeneration.



Acute light-induced retinal degeneration in *Abca4*^{-/-} mice


First, we examined the retinoid composition of the eyes of adult *Abca4*^{-/-} mice (Supplemental Fig. S1a). These mice showed no accumulation of *atRAL* when subjected to standard light cycles, a result consistent with the recent report by Adler and colleagues³². By contrast, 11*cRAL* levels were lower in *Abca4*^{-/-} mice than in wild-type mice, suggesting the slower regeneration of chromophores. An explanation of this finding is that A2E accumulates faster over time in the *Abca4*^{-/-} RPE than in the wild-type RPE (Supplemental Fig. S1b), a process that involves a delay in the removal of *atRAL* and its condensation with PE, rather than its entry into the visual retinoid cycle to regenerate 11*cRAL*. Moiseyev et al.³⁰ also described that A2E inhibits the regeneration of 11*cRAL* by binding to the RPE65 isomerase. Therefore, the lower rate of 11*cRAL* production is probably due to a defect in the two limiting steps of the visual cycle, consecutively, the reduction of *atRAL* to *atROL* facilitated by ABCR at the POS and the *trans-cis* isomerization of retinol catalyzed by RPE65 in the RPE. As we did not observe a significant decrease in scotopic photosensitivity before 10 months of age (Supplemental Fig. S1c), which corresponds to the OCT measurements reported previously³³; younger *Abca4*^{-/-} mice do not exhibit retinal degeneration without exposure to intense light. This observation highlights the difference between the late onset of *Abca4*-related retinal degeneration in mice and the early adolescent onset of macular degeneration in humans. This difference is related to human retinal features, such as the presence of a macula and a much lower photoreceptor cell density³⁵. This is a

limitation of the mouse model that can be overcome experimentally by exposure to light. Moreover, in patients with foveal sparing, vision loss was not noticed until adulthood³⁶, a clinical characteristic that, in association with lipofuscin accumulation, may be similar to the mouse phenotype^{37,38}.

We also demonstrated here that the acute form of light-induced retinal degeneration in *Abca4*^{-/-} mice provides a good opportunity to reconstruct the temporal sequence of events leading to cell death. A prevalent finding, observed by SD-OCT imaging, was hyperreflectivity in the ONL at the earliest stages of retinal damage (up to 1 day postbleaching) without thinning of the retinal outer layer (Supplemental Fig. S4). Recently, hyperreflectivity in the outer nuclear layer of Stargardt patients was documented by OCT³⁹. The authors suggested that hyperreflectivity is the result of pathological alteration of the ONL, mainly in the cones. In this study, bright light damaged both the rods and cones of *Abca4*^{-/-} mice (Supplementary Fig. S5). In the genetic context of *Abca4* deficiency, light-induced retinal lesions appear to be an accelerated pathophysiological condition, which best represents STGD1 disease in mice.

Potency of lipophenol IP-DHA to protect photoreceptors from light-induced damage

Polyphenols have long been recognized as antioxidants; more recently, some of them have been shown to have anti-carbonyl stress activities, and their application in the treatment of neurodegenerative diseases has been widely highlighted in the past few years⁴⁰. Among polyphenols,





phloroglucinol is a monomer of phlorotannin with anti-carbonyl and oxidative stress (anti-COS) activities, which also displays therapeutic potential for neurodegenerative diseases⁴¹. We previously reported the *in vitro* protective effects of phloroglucinol in outer retinal cells by reducing oxidative status and trapping *atRAL*⁴². However, a major disadvantage of phloroglucinol is its low bioavailability in the retina (unpublished data). Our strategy to improve selectivity for the retina relied on chemical modifications of the polyphenol core, leading to additional lipophilic derivatives. We synthesized phloroglucinol derivatives with DHA (omega-3, C22:6, n-3) linked on a phenolic

functional group. The choice of DHA was dictated by (1) its high content in the photoreceptor disc membrane, the photoisomerization site that produces *atRAL*, and (2) several benefits in the retina that were previously described^{43–46}. The second modification performed on phloroglucinol was the introduction of an isopropyl functional group, whose electron-donating inductive effect should adjust the nucleophilicity of the aromatic ring to trap *atRAL* most efficiently.

With regard to these data, we evaluated the effect of IP-DHA on acute light-induced retinal degeneration in 9–12-week-old mice, which required only a 1-week experimental procedure. Similar experimental paradigms were extensively reported for testing the effects of small molecules on the development of acute light-induced retinal damage in mutant mice^{18,34,47–50}. We show that the use of IP-DHA as a therapeutic agent is very effective in protecting the outer retina of *Abca4*^{-/-} mice from light-induced damage. This protective effect was dose-dependent and prevented both photoreceptor cell death and photosensitivity. The morphological (ONL/INL ratio in OCT and histological sections) and functional (a- and b-wave ERG) measurements were well correlated, suggesting a direct relationship between the number of surviving photoreceptors and the sensitivity of the retina to light stimulation. These changes also occur in the inner and outer segments of the photoreceptors, with a strong correlation of their lengths with the thickness of the nuclear layer and the light response (Supplemental Fig. S6). Together, these findings support that IP-DHA acts at the level of photoreceptor cells to maintain their integrity by preventing toxicity from the accumulation of free *atRAL*, which is produced by exposure to light in *Abca4*^{-/-} mice.

What is the mechanism of action of IP-DHA?

A major question is the mechanism of action by which IP-DHA reduces the toxicity of *atRAL*. Phloroglucinol and isopropyl-phloroglucinol form irreversible chromene adducts with *atRAL*⁴² (Supplementary Figs. S7 and S8), suggesting that the isopropyl moiety can contribute to the reactivity of phloroglucinol. However, no adduct was identified or isolated under the same conditions by mixing IP-DHA and *atRAL* in test tubes. We chemically synthesized four potential adducts that could result from an IP-DHA reaction with *atRAL* (Supplementary Figs. S7 and S8). First, we did not detect IP-DHA-*atRAL* synthesized adducts in cell extracts after coincubation of IP-DHA and *atRAL* with ARPE-19 cells or in the retina after IP-DHA IV administration. Second, we were unable to identify other adducts structurally compatible with the reaction of IP-DHA on *atRAL*. This result can be explained either by the instability of the IP-DHA-*atRAL* adducts (which would have different chemical



structures) or by the low reactivity of IP-DHA with atRAL owing to the presence of DHA. We recently reported that several enzyme systems responsible for detoxifying ROS in the cell (antioxidant/electrophile response element (ARE/EpRE)-activated enzymes, regulated by the Nrf2/Keap1 pathway²⁴) are activated by IP-DHA²³. Now, we assume that the clearance of ROS is accomplished mainly through this mechanism. Among the enzymes activated by Nrf2 pathways, some enzymes target ROS but are also able to detoxify aldehyde derivatives, such as glutathione S-transferase, which also catalyzes the formation of the glutathione–aldehyde adduct (with HNE, for instance)⁵¹. In addition, other enzyme systems could detoxify the retina, such as dehydrogenases. For example, ALDH1 and ALDH2 are described as enzymes involved in aldehyde detoxification⁵¹ and that use atRAL as a substrate⁵². Overall, these data do not support the concept of the direct trapping of atRAL by IP-DHA in its lipophenolic form but rather a reduction in atRAL toxicity by acting on enzymatic cellular defenses capable of reducing carbonyl and oxidative stress. A final mode of action may be the release of phloroglucinol and the DHA moiety by enzymatic cleavage of lipophenol, both of which have a separate protective effect. However, no protective effect of DHA ethyl ester is shown here, suggesting that supplementation with DHA alone is not sufficient to ensure photoreceptor protection.

What benefit can lipophenol provide against STGD1 and dry AMD compared to other evaluated molecules?

Therapeutic agents target visual cycle inhibition and thereby reduce *atRAL* formation^{20,21,53}. Small molecules may slow down the visual cycle by reducing the amount of circulating vitamin A (fenretinide and A1120 RBP4 antagonist) or by inhibiting the isomerase activity of RPE65 (isotretinoin, retinylamine, and EMX). *AtRAL* sequestrators (primary amines, VM-200, and EMX) and the tri-deuterated form of vitamin A (ALK-001) were able to slow the formation of bis-retinoids⁵⁴. The visual cycle modulator EMX is a primary amine that traps aldehyde in the photoreceptor, binds to and inhibits RPE65 in RPE¹⁹. Recently, the most advanced oral treatment with EMX failed to reduce geographic atrophy in phase 2b/3 trials⁵⁵. The adverse events were likely related to the drug's mechanism of action, RPE65 inhibition leading to decreased availability of 11-*cis*-retinal to the photoreceptors. New therapies that do not directly target visual cycle inhibition would be required to prevent severe adverse effects. Thus, the use of IP-DHA might be more beneficial than that of primary amines, as IP-DHA can act both on retinal toxicity and on the production of reactive carbonyl and oxygen species involved in the death of RPE and photoreceptors. The kinetics of chromophore regeneration after IP-DHA treatment (Fig. 7) revealed that IP-DHA does not impair the visual cycle. In addition, IP-DHA does not inhibit RPE65 isomerase; hence, it should not present side effects arising from this inhibitory outcome. Regarding toxicity, most primary amines are much more nucleophilic than the aromatic lipophenol; thus, they should present more potential toxicity than lipophenol. Furthermore, two natural components compose lipophenol: one polyphenolic moiety, an antioxidant compound present in foods, named phloroglucinol, an antispasmodic compound already approved by the FDA (Spasfon®), and DHA, a natural PUFA omega-3 present in food and beneficial for vision. We previously showed that the addition of isopropyl did not amend the low toxicity level of lipophenols²³. For all of these reasons, the risk of toxicity of lipophenols may be considered low. Validating this assumption, after a single injection, we observed no toxicity for over 3 months. However, to exclude all risks, future chronic treatment analyses should include toxicological studies.

In summary, based on the *in vitro* and *in vivo* biological activities of the main investigated molecule, IP-DHA, anti-COS lipophenols could represent a novel class of compounds that prevent retinal degeneration. Currently, several clinical trials on STGD1 are ongoing (<https://www.clinicaltrials.gov/>)^{56,57}. Two molecules that act on the visual cycle are in clinical phase 2/3 development (ALK001, EMX). Concomitant nonpharmacologic approaches, such as stem cell (ClinicalTrials.gov NCT02445612) or gene delivery therapies (ClinicalTrials.gov NCT01736592), and

pharmacologic treatments may be the key for efficient bitherapy. The therapeutic window for pharmacological treatment may be broader than that for other treatments if the compound shows preventive effects and is able to slow down the progression of the disease. Our approach is novel because lipophenols are able to target both carbonyl (*atRAL*) and oxidative stresses. This double reactivity represents a novel aspect of the therapeutic action of phenolic derivatives and addresses a challenge in the treatment of macular degeneration.

Acknowledgements

We would like to thank A-L. Bonnefont and M. Cren for their expertise in the IV injection of mice; C. Diez for assistance with the hyperreflectivity study; J. Bonnet for his technical assistance; the RHEM platform for the histologic preparation of paraffin sections; the INM facility for the management and maintenance of mice; and Montpellier RIO Imaging for the use of imaging tools. Fondation Stargardt, (2017-03) under the Aegis of Fondation Valentin Haüy, Retina France, ANR (ANR-18-CE18-0017-03), and SATT AxLR (18/0093) funded this research. We thank Inserm, CNRS, and University of Montpellier for their support. We disclose grant support received from Fondation Stargardt and Agence National de la Recherche.

Author details

¹Institut des Neurosciences de Montpellier, INSERM U1051, F-34091 Montpellier, France. ²Université de Montpellier, F-34091 Montpellier, France. ³Institut des Biomolécules Max Mouseron (IBMM), UMR 5247 - Université de Montpellier, CNRS, ENSCM, F-34095 Montpellier, France. ⁴Laboratoire de Biophysique Neurosensorielle, UMR INSERM 1107, Facultés de Médecine et de Pharmacie, F-63001 Clermont-Ferrand, France

Author contributions

Conceptualization and supervision: A.C., C.C., J.V., and P.B. Methodology, investigation, validation, and formal analysis: N.T., A.C., L.G., N.P., and E.M. Writing-original draft preparation: P.B. Writing-review and editing: D.C., E.M., T.D., C.C., and V.K. Funding acquisition: T.D., C.C., and P.B.

Conflict of interest

The authors declare that they have no conflict of interest.

Patent

Brabet, P., Cia, D., Guillou, L., Hamel, C., Vigor, C., Durand, T., Crauste, C., Vercauteren, J. New lipophenol compounds and uses thereof, WO2015162265A1 (2015).

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information accompanies this paper at <https://doi.org/10.1038/s12276-020-0460-7>.

Received: 18 February 2020 Revised: 18 April 2020 Accepted: 21 April 2020
Published online: 08 July 2020

References

1. Bellezza, I. Oxidative stress in age-related macular degeneration: Nrf2 as therapeutic target. *Front. Pharmacol.* **9**, 1280 (2018).
2. Hunter, J. J. et al. The susceptibility of the retina to photochemical damage from visible light. *Prog. Retin. Eye Res.* **31**, 28–42 (2012).
3. Liu, Y., Zhang, D., Wu, Y. & Ji, B. Docosahexaenoic acid aggravates photo-oxidative damage in retinal pigment epithelial cells via lipid peroxidation. *J. Photochem. Photobiol. B* **140**, 85–93 (2014).
4. Boulton, M., Rozanowska, M. & Rozanowski, B. Retinal photodamage. *J. Photochem. Photobiol. B* **64**, 144–161 (2001).

5. Noell, W. K., Walker, V. S., Kang, B. S. & Berman, S. Retinal damage by light in rats. *Invest. Ophthalmol.* **5**, 450–473 (1966).
6. Grimm, C. et al. Protection of Rpe65-deficient mice identifies rhodopsin as a mediator of light-induced retinal degeneration. *Nat. Genet.* **25**, 63–66 (2000).
7. van Norren, D. & Gorgels, T. G. The action spectrum of photochemical damage to the retina: a review of monochromatic threshold data. *Photochem. Photobiol.* **87**, 747–753 (2011).
8. Rozanowska, M. & Sarna, T. Light-induced damage to the retina: role of rhodopsin chromophore revisited. *Photochem. Photobiol.* **81**, 1305–1330 (2005).
9. Rozanowska, M., Handzel, K., Boulton, M. E. & Rozanowski, B. Cytotoxicity of all-trans-retinal increases upon photodegradation. *Photochem. Photobiol.* **88**, 1362–1372 (2012).
10. von Lintig, J., Kiser, P. D., Golczak, M. & Palczewski, K. The biochemical and structural basis for trans-to-cis isomerization of retinoids in the chemistry of vision. *Trends Biochem. Sci.* **35**, 400–410 (2010).
11. Nickell, S., Park, P. S., Baumeister, W. & Palczewski, K. Three-dimensional architecture of murine rod outer segments determined by cryoelectron tomography. *J. Cell Biol.* **177**, 917–925 (2007).
12. Tsybovsky, Y., Molday, R. S. & Palczewski, K. The ATP-binding cassette transporter ABCA4: structural and functional properties and role in retinal disease. *Adv. Exp. Med. Biol.* **703**, 105–125 (2010).
13. Parker, R. O. & Crouch, R. K. Retinal dehydrogenases (RDHs) in the visual cycle. *Exp. Eye Res.* **91**, 788–792 (2010).
14. Wright, C. B., Redmond, T. M. & Nickerson, J. M. A history of the classical visual cycle. *Prog. Mol. Biol. Transl. Sci.* **134**, 433–448 (2015).
15. Maeda, T., Golczak, M. & Maeda, A. Retinal photodamage mediated by all-trans-retinal. *Photochem. Photobiol.* **88**, 1309–1319 (2012).
16. Kim, S. R. et al. The all-trans-retinal dimer series of lipofuscin pigments in retinal pigment epithelial cells in a recessive Stargardt disease model. *Proc. Natl Acad. Sci. USA* **104**, 19273–19278 (2007).
17. Sparrow, J. R., Wu, Y., Kim, C. Y. & Zhou, J. Phospholipid meets all-trans-retinal: the making of RPE bisretinoids. *J. Lipid Res.* **51**, 247–261 (2010).
18. Maeda, A. et al. Primary amines protect against retinal degeneration in mouse models of retinopathies. *Nat. Chem. Biol.* **8**, 170–178 (2011).
19. Zhang, J. et al. Molecular pharmacodynamics of emixustat in protection against retinal degeneration. *J. Clin. Invest.* **125**, 2781–2794 (2015).
20. Kiser, P. D. et al. Rational tuning of visual cycle modulator pharmacodynamics. *J. Pharm. Exp. Ther.* **362**, 131–145 (2017).
21. Sears, A. E. et al. Towards treatment of stargardt disease: workshop organized and sponsored by the foundation fighting blindness. *Transl. Vis. Sci. Technol.* **6**, 6 (2017).
22. Crauste, C. et al. in *European Journal of Organic Chemistry* 4548–4561 (Wiley Online library, 2014).
23. Cubizolle, A. et al. Isopropyl-phloroglucinol-DHA protects outer retinal cells against lethal dose of all-trans-retinal. *J. Cell. Mol. Med.* <https://doi.org/10.1111/jcmm.15135> (2020).
24. Reinisalo, M., Karlund, A., Koskela, A., Kaamiranta, K. & Karjalainen, R. O. Polyphenol stilbenes: molecular mechanisms of defence against oxidative stress and aging-related diseases. *Oxid. Med. Cell Longev.* **2015**, 340520 (2015).
25. Drouin, G. et al. Comparative effects of dietary n-3 docosapentaenoic acid (DPA), DHA and EPA on plasma lipid parameters, oxidative status and fatty acid tissue composition. *J. Nutr. Biochem.* **63**, 186–196 (2019).
26. Kielar, M. L., Jeyarajah, D. R., Zhou, X. J. & Lu, C. Y. Docosahexaenoic acid ameliorates murine ischemic acute renal failure and prevents increases in mRNA abundance for both TNF-alpha and inducible nitric oxide synthase. *J. Am. Soc. Nephrol.* **14**, 389–396 (2003).
27. Ferguson, L. R., Balaiya, S., Grover, S. & Chalam, K. V. Modified protocol for in vivo imaging of wild-type mouse retina with customized miniature spectral domain optical coherence tomography (SD-OCT) device. *Biol. Proced. Online* **14**, 9 (2012).
28. Chekroud, K. et al. Fatp1 deficiency affects retinal light response and dark adaptation, and induces age-related alterations. *PLoS ONE* **7**, e50231 (2012).
29. Cubizolle, A., Guillou, L., Mollereau, B., Hamel, C. P. & Brabet, P. Fatty acid transport protein 1 regulates retinoid metabolism and photoreceptor development in mouse retina. *PLoS ONE* **12**, e0180148 (2017).
30. Moiseyev, G. et al. Inhibition of the visual cycle by A2E through direct interaction with RPE65 and implications in Stargardt disease. *Proc. Natl Acad. Sci. USA* **107**, 17551–17556 (2010).
31. Wu, L., Ueda, K., Nagasaki, T. & Sparrow, J. R. Light damage in Abca4 and Rpe65rd12 mice. *Invest. Ophthalmol. Vis. Sci.* **55**, 1910–1918 (2014).
32. Adler, L. T., Chen, C. & Koutalos, Y. All-trans retinal levels and formation of lipofuscin precursors after bleaching in rod photoreceptors from wild type and Abca4(–/–) mice. *Exp. Eye Res.* **155**, 121–127 (2017).
33. Wu, L., Nagasaki, T. & Sparrow, J. R. Photoreceptor cell degeneration in Abca4(–/–) mice. *Adv. Exp. Med. Biol.* **664**, 533–539 (2010).
34. Bavik, C. et al. Visual cycle modulation as an approach toward preservation of retinal integrity. *PLoS ONE* **10**, e0124940 (2015).
35. Volland, S., Esteve-Rudd, J., Hoo, J., Yee, C. & Williams, D. S. A comparison of some organizational characteristics of the mouse central retina and the human macula. *PLoS ONE* **10**, e0125631 (2015).
36. Fujinami, K. et al. Clinical and molecular analysis of Stargardt disease with preserved foveal structure and function. *Am. J. Ophthalmol.* **156**, 487–501 (2013). e481.
37. Charbel Issa, P. et al. Fundus autofluorescence in the Abca4(–/–) mouse model of Stargardt disease—correlation with accumulation of A2E, retinal function, and histology. *Invest. Ophthalmol. Vis. Sci.* **54**, 5602–5612 (2013).
38. Dysli, C., Wolf, S., Hatz, K. & Zinkernagel, M. S. Fluorescence lifetime imaging in stargardt disease: potential marker for disease progression. *Invest. Ophthalmol. Vis. Sci.* **57**, 832–841 (2016).
39. Khan, K. N. et al. Early patterns of macular degeneration in ABCA4-associated retinopathy. *Ophthalmology* **125**, 735–746 (2018).
40. Bhullar, K. S. & Rupasinghe, H. P. Polyphenols: multipotent therapeutic agents in neurodegenerative diseases. *Oxid. Med. Cell Longev.* **2013**, 891748 (2013).
41. Ryu, J. et al. Phloroglucinol attenuates motor functional deficits in an animal model of Parkinson's disease by enhancing Nrf2 activity. *PLoS ONE* **8**, e71178 (2013).
42. Cia, D. et al. Phloroglucinol protects retinal pigment epithelium and photoreceptor against all-trans-retinal-induced toxicity and inhibits A2E formation. *J. Cell Mol. Med.* **20**, 1651–1663 (2016).
43. Mukherjee, P. K., Marcheselli, V. L., Serhan, C. N. & Bazan, N. G. Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. *Proc. Natl Acad. Sci. USA* **101**, 8491–8496 (2004).
44. Dornstauder, B. et al. Dietary docosahexaenoic acid supplementation prevents age-related functional losses and A2E accumulation in the retina. *Invest. Ophthalmol. Vis. Sci.* **53**, 2256–2265 (2012).
45. Rice, D. S. et al. Adiponectin receptor 1 conserves docosahexaenoic acid and promotes photoreceptor cell survival. *Nat. Commun.* **6**, 6228 (2015).
46. Shindou, H. et al. Docosahexaenoic acid preserves visual function by maintaining correct disc morphology in retinal photoreceptor cells. *J. Biol. Chem.* **292**, 12054–12064 (2017).
47. Maeda, A. et al. Involvement of all-trans-retinal in acute light-induced retinopathy of mice. *J. Biol. Chem.* **284**, 15173–15183 (2009).
48. Maeda, A. et al. Effects of potent inhibitors of the retinoid cycle on visual function and photoreceptor protection from light damage in mice. *Mol. Pharmacol.* **70**, 1220–1229 (2006).
49. Qi, S., Wang, C., Song, D., Song, Y. & Dunaief, J. L. Intraperitoneal injection of (-)-Epigallocatechin-3-gallate protects against light-induced photoreceptor degeneration in the mouse retina. *Mol. Vis.* **23**, 171–178 (2017).
50. Shin, Y. et al. A novel RPE65 inhibitor CU239 suppresses visual cycle and prevents retinal degeneration. *Biochim. Biophys. Acta Mol. Basis Dis.* **1864**, 2420–2429 (2018).
51. Aldini, G., Carini, M., Yeum, K. J. & Vistoli, G. Novel molecular approaches for improving enzymatic and nonenzymatic detoxification of 4-hydroxynonenal: toward the discovery of a novel class of bioactive compounds. *Free Radic. Biol. Med.* **69**, 145–156 (2014).
52. Koppaka, V. et al. Aldehyde dehydrogenase inhibitors: a comprehensive review of the pharmacology, mechanism of action, substrate specificity, and clinical application. *Pharmacol. Rev.* **64**, 520–539 (2012).
53. Hussain, R. M., Gregori, N. Z., Ciulla, T. A. & Lam, B. L. Pharmacotherapy of retinal disease with visual cycle modulators. *Expert Opin. Pharmacother.* **19**, 471–481 (2018).
54. Ma, L., Kaufman, Y., Zhang, J. & Washington, I. C20-D3-vitamin A slows lipofuscin accumulation and electrophysiological retinal degeneration in a mouse model of Stargardt disease. *J. Biol. Chem.* **286**, 7966–7974 (2011).
55. Rosenfeld, P. J. et al. Emixustat hydrochloride for geographic atrophy secondary to age-related macular degeneration: a randomized clinical trial. *Ophthalmology* **125**, 1556–1567 (2018).
56. Lu, L. J., Liu, J. & Adelman, R. A. Novel therapeutics for Stargardt disease. *Graefes Arch. Clin. Exp. Ophthalmol.* **255**, 1057–1062 (2017).
57. Hussain, R. M. et al. Stargardt macular dystrophy and evolving therapies. *Expert Opin. Biol. Ther.* **18**, 1049–1059 (2018).